SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 27, 2003
BIOTRANSPLANT INCORPORATED
(Exact name of registrant as specified in its charter)
DELAWARE 000-28324 04-3119555
------------------------------- ----------------------- -------------------
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
200 Boston Avenue
Medford, MA 02155
---------------------------- -------------------
(Address of principal (Zip Code)
executiveoffices)
Registrant's telephone number, including area code: (781) 393-8500
Building 75, Third Avenue
Charlestown Navy Yard
Charlestown, MA
-----------------------------------------------------------
(Former name or former address, if changed since last report)
Item 5. Other Events.
On February 27, 2003, BioTransplant Incorporated issued a press release
announcing that the Company and its wholly-owned subsidiary, Eligix, Inc., have
filed voluntary petitions for reorganization under Chapter 11 of the U.S.
Bankruptcy Code. The filings were made in U.S. Bankruptcy Court in Boston,
Massachusetts. A copy of the press release announcing the filings is attached as
Exhibit 99.1.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits.
See Exhibit Index attached hereto.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date: February 28, 2003 BIOTRANSPLANT INCORPORATED
By: /s/ Donald B. Hawthorne
-----------------------------------
Donald B. Hawthorne
President and Chief Executive Officer
EXHIBIT INDEX
EXHIBIT NO. EXHIBIT
----------- -------
Exhibit 99.1 Press Release dated February 27, 2003